{
    "name": "bupropion/naltrexone",
    "comment": "Rx",
    "other_names": [
        "Contrave"
    ],
    "classes": [
        "Antidepressants",
        "Dopamine Reuptake Inhibitors",
        "Opioid Antagonists"
    ],
    "source": "https://reference.medscape.com/drug/contrave-bupropion-naltrexone-999933",
    "pregnancy": {
        "common": [
            "Weight loss offers no benefit to a pregnant patient and may cause fetal harm; when a pregnancy is recognized, advise pregnant patient of risk to fetus, and discontinue therapy; available pharmacovigilance data and data from clinical trials with individual components of combination drug use in pregnant patients have not demonstrated a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Bupropion",
                "description": [
                    "Data from epidemiological studies of pregnant patients exposed to bupropion in first trimester have not identified an increased risk of congenital malformations overall",
                    "When bupropion was administered to pregnant rats during organogenesis, there was no evidence of fetal malformations at doses up to approximately 20 times maximum recommended human dose (MRHD) of 360 mg/day",
                    "When given to pregnant rabbits during organogenesis, non-dose–related increases in incidence of fetal malformations, and skeletal variations were observed at doses approximately twice the MRHD and greater; decreased fetal weights were seen at doses 5 times MRHD and greater"
                ]
            },
            {
                "type": "Naltrexone",
                "description": [
                    "Limited case report data of pregnant patients exposed to naltrexone in first trimester have not identified an increased risk of congenital malformations overall; daily oral administration of naltrexone during period of organogenesis has been shown to increase incidence of early fetal loss in rats and rabbits at doses ≥15 times and ≥60 times MRHD of 32 mg/day respectively",
                    "There was no evidence of fetal malformations in rats and rabbits at doses up to approximately 100 and 200 times the MHRD, respectively",
                    "Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data from published literature report the presence of bupropion and its metabolites in human milk",
            "Limited data from postmarketing reports with bupropion use during lactation have not identified a clear association of adverse effects on a breastfed infant",
            "Naltrexone and its major metabolite, 6 β-naltrexol, are present in human milk; there are no data on bupropion, naltrexone, or their metabolites on milk production; the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug combination or from mother’s underlying condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Not approved for treatment of major depressive disorder or psychiatric disorders",
                "Antidepressants like bupropion increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials but were not seen in patients ≥24 years and a lower risk was seen in patients ≥65 years; patients of all ages should be monitored closely for suicidal thoughts and behaviors",
                "Serious neuropsychiatric reactions reported in patients taking bupropion for smoking cessation that occurred during therapy or while discontinuing therapy; patients should be monitored for neuropsychiatric reactions"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Uncontrolled hypertension",
                "Seizure disorder or a history of seizures",
                "Use of other bupropion-containing products",
                "Bulimia or anorexia nervosa, which may increase risk of seizures",
                "Long-term opioid or opiate agonists use or acute opiate withdrawal",
                "Patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs",
                "Within 14 days of monoamine oxidase inhibitor therapy",
                "Hypersensitivity",
                "Pregnancy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Monitor patients for suicidal ideation or behavior and for unusual changes in behavior (see black box warning)",
                "Discontinue therapy and do not restart if seizure occurs while on therapy; use caution when prescribing to patients with predisposing risk factors for seizures",
                "Not for administration to patients receiving long-term opioids, owing to naltrexone component (opioid antagonist); discontinue therapy if long-term opiate therapy required",
                "Following therapy, patients may be more sensitive to opioids, even at lower doses",
                "A patient should not attempt to overcome naltrexone opioid blockade by administering large amounts of exogenous opioids; may lead to fatal overdose",
                "Opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before therapy is initiated; opioid-free interval of a minimum of 7-10 days is recommended for patients previously dependent on short-acting opioids; patients transitioning from buprenorphine or methadone may need as long as 2 weeks",
                "Blood pressure and pulse should be measured prior to starting therapy and should be monitored at regular intervals, particularly among patients with controlled hypertension prior to treatment",
                "Discontinue therapy if symptoms or signs of acute hepatitis occur",
                "Screen patients for a history of bipolar disorder and the presence of risk factors for bipolar disorder; therapy was not studied in patients receiving antidepressant medications patients with a history of bipolar disorder or recent hospitalization foor psychiatric illness were excluded from clinical trials",
                "Angle-closure attack may occur in patients with anatomically narrow angles that do not have a patent iridectomy",
                "Measure blood glucose levels prior to and during therapy; patients who develop hypoglycemia after initiating Contrave therapy should adjust antidiabetic drug regimen",
                "Use caution in patients with history of tumor or infection of the brain or spine",
                "Initiation of therapy in patients receiving linezolid or intravenous (IV) methylene blue",
                "Use caution in hepatic impairment",
                "May precipitate a manic, mixed, or hypomanic episode; risk higher in patients with bipolar disorders or have risk factors for bipolar disorder, including family history of bipolar disorder, suicide, or depression; not FDA approved for bipolar depression",
                "Some patients who stopped smoking reported to have experienced symptoms of nicotine withdrawal, including depressed mood; depression, rarely including suicidal ideation, reported in smokers undergoing a smoking cessation attempt without medication; however, some of these adverse events occurred in patients taking bupropion who continued to smoke",
                "Neuropsychiatric adverse events reported in patients without and with pre-existing psychiatric disease; some patients experienced worsening of their psychiatric illnesses; observe patients for occurrence of neuropsychiatric adverse events; patient should stop therapy and contact healthcare provider immediately if agitation, depressed mood, or changes in behavior or thinking that are not typical for patient are observed, or if patient develops suicidal ideation or suicidal behavior; symptoms may persist after discontinuation of therapy; in some cases; monitoring and supportive care should be provided until symptoms resolve"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "bupropion increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pimozide",
            "description": {
                "common": "bupropion will increase the level or effect of pimozide by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Both bupropion and hydroxybupropion (major metabolite) are considered strong CYP2D6 inhibitors; additionally, bupropion and pimozide lower seizure threshold"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rasagiline",
            "description": {
                "common": "rasagiline and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine and bupropion both increase  dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropion"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP2B6 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bremelanotide",
            "description": {
                "common": "bremelanotide will decrease the level or effect of naltrexone by  Other (see comment). Avoid or Use Alternate Drug. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. Avoid using bremelanotide with an orally administered naltrexone-containing product that is intended to treat alcohol and opioid addiction due to the potential for naltrexone treatment failure."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caffeine",
            "description": {
                "common": "caffeine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clomipramine",
            "description": {
                "common": "bupropion will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "bupropion and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Avoid or Use Alternate Drug. Coadministration may decrease plasma concentrations of CYP2B6 substrates owing to fexinidazole inducing CYP2B6."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine increases toxicity of bupropion by Other (see comment). Avoid or Use Alternate Drug. \nComment: May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iobenguane I 131",
            "description": {
                "common": "bupropion will decrease the level or effect of iobenguane I 131 by  Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "linezolid",
            "description": {
                "common": "bupropion, linezolid. serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "bupropion and lorcaserin both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylene blue",
            "description": {
                "common": "bupropion and methylene blue both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "bupropion will increase the level or effect of metoclopramide intranasal by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of metoclopramide intranasal and strong CYP2D6 inhibitors is not recommended since the metoclopramide intranasal dose cannot be adjusted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "naldemedine",
            "description": {
                "common": "naldemedine, naltrexone.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive opioid receptor anatagonism and increased risk of opioid withdrawal."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "naloxegol",
            "description": {
                "common": "naloxegol, naltrexone.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration; potential for additive effect of opioid receptor anatagonism and increased risk of opioid withdrawal."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acamprosate",
            "description": {
                "common": "naltrexone increases levels of acamprosate by unspecified interaction mechanism. Use Caution/Monitor. No dosage adjustment is needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "amantadine, bupropion. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential CNS toxicity d/t synergistic central dopamine effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifampridine",
            "description": {
                "common": "bupropion increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of naltrexone by  increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and may decrease systemic exposure of drugs that are UGT substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "bupropion will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "bupropion will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "bupropion will increase the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone [benzhydrocodone is prodrug of hydrocodone]) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "bupropion will increase the level or effect of betaxolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "bupropion will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer half of the usual brexpiprazole dose when coadministered with strong CYP2D6 inhibitors. If also administered with a strong/moderate CYP3A4 inhibitor, administer a quarter of brexpiprazole dose. NOTE: In MDD clinical trials, brexpiprazole dosage was not adjusted for strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine); thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital, bupropion. increasing metabolism. Use Caution/Monitor. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol, bupropion. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "bupropion will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP2B6 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "bupropion will increase the level or effect of chloroquine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "bupropion will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinacalcet",
            "description": {
                "common": "bupropion will increase the level or effect of cinacalcet by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "bupropion will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "clopidogrel will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Plasma concentrations of bupropion may be significantly increased when coadministered with clopidogrel or other CYP2B6 inhibitors. The increase in plasma bupropion concentrations may cause an increase in adverse reactions including tremor, headache, insomnia, dry mouth, nausea, or seizures."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "bupropion will decrease the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents the conversion of codeine to its active metabolite morphine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "bupropion and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "bupropion will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "bupropion will increase the level or effect of deutetrabenazine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Strong CYP2D6 inhibitors increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine by approximately 3-fold. Do not exceed 18 mg/dose and 36 mg/day of deutetrabenazine if coadministered with strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "bupropion will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine transdermal",
            "description": {
                "common": "bupropion will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "bupropion will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "diazepam intranasal, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and bupropion both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "bupropion will decrease the level or effect of digoxin by  Other (see comment). Use Caution/Monitor. Monitor for decreased digoxin concentrations; bupropion may induce OATP4C1 transporter, which is involved in digoxin renal elimination"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "bupropion will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronabinol",
            "description": {
                "common": "naltrexone increases effects of dronabinol by Other (see comment). Use Caution/Monitor. \nComment: Naltrexone may enhance therapeutic effects of cannabinoids. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "bupropion will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of bupropion by  increasing metabolism. Use Caution/Monitor. Coadministration with hepatic inducers reduced bupropion AUC and Cmax; hydroxybupropion (active metabolite) Cmax was increased "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "bupropion increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of bupropion by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "fenfluramine, bupropion.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "bupropion will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "bupropion will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Coadministration of bupropion and flecainide should be approached with caution and should be initiated at the lower end of the dose range of flecainide. If bupropion is added to the treatment regimen of a patient already receiving flecainide, consider decreasing the dose of flecainide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "bupropion will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "bupropion will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil, bupropion.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "galantamine",
            "description": {
                "common": "bupropion will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "bupropion and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "bupropion will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "bupropion will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "bupropion will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "bupropion will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "bupropion will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioflupane I 123",
            "description": {
                "common": "bupropion decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, bupropion.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant will decrease the level or effect of bupropion by  affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Monitor CYP2B6 substrate for adequate clinical response. Consider increasing the CYP2B6 substrate dose according to specific prescribing recommendations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "bupropion increases effects of levodopa by pharmacodynamic synergism. Use Caution/Monitor. There is a higher incidence of adverse reactions with concurrent use of bupropion with levodopa. Use small initial dosages and small, gradual dosage increases of bupropion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "lisdexamfetamine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "bupropion will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofexidine",
            "description": {
                "common": "bupropion will increase the level or effect of lofexidine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Concomitant use of lofexidine with strong CYP2D6 inhibitors may increase lofexidine plasma levels. Monitor for symptoms of orthostasis and bradycardia if coadministered with a CYP2D6 inhibitor. Consider lofexidine dose reduction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loratadine",
            "description": {
                "common": "bupropion will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabilone",
            "description": {
                "common": "naltrexone increases effects of nabilone by Other (see comment). Use Caution/Monitor. \nComment: Naltrexone may enhance therapeutic effects of cannabinoids. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil, bupropion. increasing metabolism. Minor/Significance Unknown. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of bupropion by increasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefpirome",
            "description": {
                "common": "cefpirome increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "bupropion will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "bupropion will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "encainide",
            "description": {
                "common": "bupropion will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol, bupropion.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meperidine",
            "description": {
                "common": "meperidine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil, bupropion. increasing metabolism. Minor/Significance Unknown. Decr levels of bupropion, but incr levels of active metabolites. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicotine inhaled",
            "description": {
                "common": "bupropion, nicotine inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypertension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicotine intranasal",
            "description": {
                "common": "bupropion, nicotine intranasal.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypertension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perhexiline",
            "description": {
                "common": "bupropion will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promazine",
            "description": {
                "common": "bupropion will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine increases toxicity of bupropion by unspecified interaction mechanism. Minor/Significance Unknown. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tropisetron",
            "description": {
                "common": "bupropion will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "32.5"
        },
        {
            "name": "Constipation",
            "percent": "19.2"
        },
        {
            "name": "Headache",
            "percent": "17.6"
        },
        {
            "name": "Vomiting",
            "percent": "10.7"
        },
        {
            "name": "Dizziness",
            "percent": "9.9"
        },
        {
            "name": "Insomnia",
            "percent": "9.2"
        },
        {
            "name": "Dry mouth",
            "percent": "8.1"
        },
        {
            "name": "Diarrhea",
            "percent": "7.1"
        },
        {
            "name": "Anxiety",
            "percent": "4.2"
        },
        {
            "name": "Hot flash",
            "percent": "4.2"
        },
        {
            "name": "Fatigue",
            "percent": "4"
        },
        {
            "name": "Tremor",
            "percent": "4"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "3.5"
        },
        {
            "name": "Viral gastroenteritis",
            "percent": "3.5"
        },
        {
            "name": "Influenza",
            "percent": "3.4"
        },
        {
            "name": "Tinnitus",
            "percent": "3.3"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3.3"
        },
        {
            "name": "Hypertension",
            "percent": "3.2"
        },
        {
            "name": "Abdominal pain",
            "percent": "2.8"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "2.6"
        },
        {
            "name": "Irritability",
            "percent": "2.6"
        },
        {
            "name": "Increased blood pressure",
            "percent": "2.4"
        },
        {
            "name": "Dysgeusia",
            "percent": "2.4"
        },
        {
            "name": "Rash",
            "percent": "2.4"
        },
        {
            "name": "Muscle strain",
            "percent": "2.2"
        },
        {
            "name": "Palpitations",
            "percent": "2.1"
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Motion sickness",
            "percent": null
        },
        {
            "name": "Lower abdominal pain",
            "percent": null
        },
        {
            "name": "Eructation",
            "percent": null
        },
        {
            "name": "Lip swelling",
            "percent": null
        },
        {
            "name": "Hematochezia",
            "percent": null
        },
        {
            "name": "Hernia",
            "percent": null
        },
        {
            "name": "Feeling jittery",
            "percent": null
        },
        {
            "name": "Thirst",
            "percent": null
        },
        {
            "name": "Feeling hot",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Cholecystitis",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Staphylococcal infection",
            "percent": null
        },
        {
            "name": "Kidney infection",
            "percent": null
        },
        {
            "name": "Increased creatinine clearance",
            "percent": null
        },
        {
            "name": "Increased hepatic enzymes",
            "percent": null
        },
        {
            "name": "Decreased hematocrit",
            "percent": null
        },
        {
            "name": "Dehydration",
            "percent": null
        },
        {
            "name": "Intervertebral disc protrusion",
            "percent": null
        },
        {
            "name": "Jaw pain",
            "percent": null
        },
        {
            "name": "Disturbance in attention",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Intention tremor",
            "percent": null
        },
        {
            "name": "Balance disorder",
            "percent": null
        },
        {
            "name": "Memory impairment",
            "percent": null
        },
        {
            "name": "Amnesia",
            "percent": null
        },
        {
            "name": "Mental impairment",
            "percent": null
        },
        {
            "name": "Presyncope",
            "percent": null
        },
        {
            "name": "Abnormal dreams",
            "percent": null
        },
        {
            "name": "Nervousness",
            "percent": null
        },
        {
            "name": "Dissociation",
            "percent": null
        },
        {
            "name": "feeling spacy",
            "percent": null
        },
        {
            "name": "Tension",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Mood swings",
            "percent": null
        },
        {
            "name": "Vaginal hemorrhage",
            "percent": null
        },
        {
            "name": "Irregular menstruation",
            "percent": null
        },
        {
            "name": "Erectile dysfunction",
            "percent": null
        },
        {
            "name": "Vulvovaginal dryness",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Loss of consciousness",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        }
    ]
}